“…(CSF3/G-CSF) [11][12][13][14][15], chemokine (C-X-C motif) ligand2 (CXCL2) [16,17], chemokine (C-X-C motif) ligand 12 (CXCL12/SDF1) [18][19][20][21], endothelin 1 (ET1) [22], fibroblast growth factor 1 (FGF 1) [23], hepatocyte growth factor (HGF) [24,25], hypoxia inducible factor 1 alpha (HIF1a) [26], leptin [27], matrix metallopeptidase 9 (MMP9) [18,28,29], serpine/plasminogen activator inhibitor 1 (PAI1) [29][30][31], platelet-derived growth factor-A (PDGF-A) [18,32], transforming growth factor alpha (TGFa) [33,34], transforming growth factor beta 1 (TGFb1) [35,36], tenomodulin (TNMD) [37], and troponin I type 2 (TNNI2) [38,39]. Factors known to be involved in lymphangiogenesis such as fibroblast growth factor 2 (FGF 2) [40,41], c-fos induced growth factor (FIGF/VEGF-D) [42,43], forkhead box C 2 (FOXC2) [44][45][46], and prospero homeobox 1 (PROX1) [46][47][48][49] are also included in the study.…”